Sign In
Buy ME
$0.606
+0 (+0%)
At Close: Sep 16, 2025
23andMe board resigns in feud over CEO Anne Wojcicki's plan to take company private
12:54pm, Wednesday, 18'th Sep 2024
The board resignations followed CEO Anne Wojcicki's latest proposal to take the company private.
23andMe's stock tumbles 7% after independent directors quit in clash with CEO over buyout plan
07:06am, Wednesday, 18'th Sep 2024
The directors said the decision comes after months of work that failed to result in an actionable plan that meets the interests of non-affiliated shareholders.
23andMe sees independent board directors quit en masse
01:46am, Wednesday, 18'th Sep 2024
23andMe, the personal genomics company, went public in early 2021 via a merger with a blank check company that valued it at $3.5 billion. Then its fortunes began to sink.
23andMe CEO Anne Wojcicki 'surprised and disappointed' by board resignations: Read the memo
11:29pm, Tuesday, 17'th Sep 2024
All seven independent directors resigned from 23andMe's board Tuesday, effective immediately. The directors had formed a special committee in March tasked with helping the struggling company find a ne
23andMe independent directors quit board over unsatisfactory buyout plan from CEO
05:28pm, Tuesday, 17'th Sep 2024
The independent directors of genetic testing firm 23andMe said on Tuesday they have resigned from the company's board after not receiving a satisfactory take-private offer from CEO Anne Wojcicki.
Independent Directors of 23andMe Resign from Board
04:26pm, Tuesday, 17'th Sep 2024
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- The independent directors of the Board of 23andMe Holding Co. (Nasdaq: ME), today sent the following letter to Anne Wojcicki, Chief Exec
23andMe Reportedly Paying $30 Million to Settle Data Breach Suit
04:25pm, Sunday, 15'th Sep 2024
23andMe will reportedly pay $30 million to settle a lawsuit tied to a data breach. As Reuters reported Friday (Sept.
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and a
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response
23andMe settles data breach lawsuit for $30 million
12:41pm, Friday, 13'th Sep 2024
23andMe will pay $30 million and provide three years of security monitoring to settle a lawsuit accusing the genetics testing company of failing to protect the privacy of 6.9 million customers whose p
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
04:05pm, Thursday, 12'th Sep 2024
23andMe, National Human Genome Research Institute, and Johns Hopkins University conducted collaborative research that studied sickle cell trait in a diverse population 23andMe, National Human Genome R
23andMe CEO Wojcicki open to third-party takeover proposals for firm, filing shows
06:06pm, Wednesday, 11'th Sep 2024
23andMe co-founder and chief executive Anne Wojcicki would be open to considering third-party takeover proposals for the company, a regulatory filing showed on Wednesday.
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
07:30am, Tuesday, 03'rd Sep 2024
Preliminary data from renal cancer and TMB-H/MSI-H cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
07:30am, Wednesday, 28'th Aug 2024
In conjunction with this new offering, 23andMe, Lemonaid Health's parent company, recently launched study focused on the role genetics may play in effectiveness and side effects of GLP-1s In conjuncti
23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data
12:15pm, Thursday, 15'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed cl
